Pancreatic Cancer Market Landscape Discussed by GBI Research in Topical Study Available at MarketPublishers.com
21 Jul 2015 • by Natalie Aster
LONDON – The dismal prognosis of pancreatic cancer patients has emphasised a huge need for novel and enhanced treatment approaches, which is not being met by today’s market.
A highly active the treatment pipeline for pancreatic cancer contains a host of products with varying mechanisms of action (MoA) and types of molecules, which provides a sharp contrast to the presently chemotherapy dominated market. Within the pancreatic cancer treatment pipeline, 185 products are categorised as first-in-class, accounting for 52% of all products with a disclosed molecular target. However, most development is in the early phases, which means a considerable proportion of therapies will not likely reach the market in the short run.
Whilst the pipeline contains 447 therapeutics across all development stages, as compared with 209 products marketed at present, around 75% of therapies are currently in phase I trials or earlier.
An extremely different pipeline and market composition indicates that the approach to pancreatic cancer treatment is altering and innovative first-in-class treatment options are playing a major role in this.
Topical research study “Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation” developed by GBI Research offers an in-depth look at innovations in pancreatic cancer treatment in light of the overall pipeline and present-day market landscape. The report gives an in-depth overview of the disease; evaluates the composition of the market and pinpoints current unmet needs; provides true insights into the gaps existing in the pancreatic cancer treatment marketplace; offers an all-round assessment and ranking of first-in-class products in accordance with their therapeutic potential. Furthermore, the research publication draws up a comprehensive picture of the deals landscape encompassing first-in-class products in pancreatic cancer therapeutics, and identifies key commercial opportunities by analyzing the various trends in co-development and licensing deals.
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
Published: June, 2015
Price: US$ 6,995.00
More reports by the publisher can be found at GBI Research page.